These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 39430181

  • 1. Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy.
    Li J, Lv J, Wong MG, Shi S, Zan J, Monaghan H, Perkovic V, Zhang H, TESTING Study Biomarker Group.
    Kidney Int Rep; 2024 Oct; 9(10):3016-3026. PubMed ID: 39430181
    [Abstract] [Full Text] [Related]

  • 2. Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status.
    Gong S, Jin S, Li Y, Jiang W, Zhang Z, Shen Z, Wang J, Zhou H, Liu X, Xu X, Ding X, Shi Y, Liu H.
    Front Immunol; 2021 Oct; 12():769802. PubMed ID: 35003086
    [Abstract] [Full Text] [Related]

  • 3. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF.
    Cochrane Database Syst Rev; 2015 Aug 03; (8):CD003965. PubMed ID: 26235292
    [Abstract] [Full Text] [Related]

  • 4. Non-immunosuppressive treatment for IgA nephropathy.
    Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF.
    Cochrane Database Syst Rev; 2024 Feb 01; 2(2):CD003962. PubMed ID: 38299639
    [Abstract] [Full Text] [Related]

  • 5. Urinary Soluble CD163 in Active Renal Vasculitis.
    O'Reilly VP, Wong L, Kennedy C, Elliot LA, O'Meachair S, Coughlan AM, O'Brien EC, Ryan MM, Sandoval D, Connolly E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JS, Heeringa P, Buckley C, O'Brien C, Finn S, Cohen CD, Lindemeyer MT, Hickey FB, O'Hara PV, Feighery C, Moran SM, Mellotte G, Clarkson MR, Dorman AJ, Murray PT, Little MA.
    J Am Soc Nephrol; 2016 Sep 01; 27(9):2906-16. PubMed ID: 26940094
    [Abstract] [Full Text] [Related]

  • 6. Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis.
    Gupta R, Yadav A, Aggarwal A.
    Clin Rheumatol; 2021 Mar 01; 40(3):941-948. PubMed ID: 32809146
    [Abstract] [Full Text] [Related]

  • 7. Immunosuppressive agents for treating IgA nephropathy.
    Natale P, Palmer SC, Ruospo M, Saglimbene VM, Craig JC, Vecchio M, Samuels JA, Molony DA, Schena FP, Strippoli GF.
    Cochrane Database Syst Rev; 2020 Mar 12; 3(3):CD003965. PubMed ID: 32162319
    [Abstract] [Full Text] [Related]

  • 8. Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis.
    Endo N, Tsuboi N, Furuhashi K, Shi Y, Du Q, Abe T, Hori M, Imaizumi T, Kim H, Katsuno T, Ozaki T, Kosugi T, Matsuo S, Maruyama S.
    Nephrol Dial Transplant; 2016 Dec 12; 31(12):2023-2033. PubMed ID: 27242373
    [Abstract] [Full Text] [Related]

  • 9. Immunosuppressive therapy for IgA nephropathy in children.
    Alladin A, Hahn D, Hodson EM, Ravani P, Pfister K, Quinn RR, Samuel SM.
    Cochrane Database Syst Rev; 2024 Jun 12; 6(6):CD015060. PubMed ID: 38864363
    [Abstract] [Full Text] [Related]

  • 10. Intensity of Macrophage Infiltration in Glomeruli Predicts Response to Immunosuppressive Therapy in Patients with IgA Nephropathy.
    Xie D, Zhao H, Xu X, Zhou Z, Su C, Jia N, Liu Y, Hou FF.
    J Am Soc Nephrol; 2021 Dec 01; 32(12):3187-3196. PubMed ID: 34670812
    [Abstract] [Full Text] [Related]

  • 11. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
    Greisen SR, Møller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Deleuran B.
    Clin Exp Rheumatol; 2015 Dec 01; 33(4):498-502. PubMed ID: 25962601
    [Abstract] [Full Text] [Related]

  • 12. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K, Barrera F, Møller HJ, Bibby BM, Vilstrup H, George J, Grønbaek H.
    Hepatology; 2014 Aug 01; 60(2):521-30. PubMed ID: 24623375
    [Abstract] [Full Text] [Related]

  • 13. High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: an observational cross-sectional study.
    Gong WY, Liu M, Luo D, Liu FN, Yin LH, Li YQ, Zhang J, Peng H.
    BMC Nephrol; 2019 Apr 30; 20(1):150. PubMed ID: 31039758
    [Abstract] [Full Text] [Related]

  • 14. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
    Peng QL, Zhang YL, Shu XM, Yang HB, Zhang L, Chen F, Lu X, Wang GC.
    J Rheumatol; 2015 Jun 30; 42(6):979-87. PubMed ID: 25877505
    [Abstract] [Full Text] [Related]

  • 15. The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy.
    Kim D, Lv J, Hladunewich M, Jha V, Hooi LS, Monaghan H, Shan S, Reich HN, Barbour S, Billot L, Zhang H, Perkovic V, Wong MG, TESTING trial steering committee.
    Kidney Int Rep; 2024 Jul 30; 9(7):2168-2179. PubMed ID: 39081761
    [Abstract] [Full Text] [Related]

  • 16. Clinical-pathologic significance of CD163 positive macrophage in IgA nephropathy patients with crescents.
    Li J, Liu CH, Gao B, Xu DL.
    Int J Clin Exp Med; 2015 Jul 30; 8(6):9299-305. PubMed ID: 26309588
    [Abstract] [Full Text] [Related]

  • 17. Mizoribine halts kidney fibrosis in childhood IgA nephropathy: association with modulation of M2-type macrophages.
    Ikezumi Y, Yoshikane M, Kondoh T, Matsumoto Y, Kumagai N, Kaneko M, Hasegawa H, Yamada T, Suzuki T, Nikolic-Paterson DJ.
    Pediatr Nephrol; 2023 Jun 30; 38(6):1831-1842. PubMed ID: 36357635
    [Abstract] [Full Text] [Related]

  • 18. The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: a cohort study.
    Wang Z, Jiang Y, Chen P, Wang J, Zhang X, Huang B, Zhou X, Shi S, Liu L, Lv J, Zhang H.
    Nephrol Dial Transplant; 2022 Oct 19; 37(11):2119-2127. PubMed ID: 35104893
    [Abstract] [Full Text] [Related]

  • 19. Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy.
    Neuhaus J, Bauer F, Fitzner C, Hilgers RD, Seibert F, Babel N, Doevelaar A, Eitner F, Floege J, Rauen T, Westhoff TH.
    Kidney Blood Press Res; 2018 Oct 19; 43(5):1563-1572. PubMed ID: 30347407
    [Abstract] [Full Text] [Related]

  • 20. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A, Støy S, Thomsen KL, Hvas CL, Agnholt J, Dahlerup JF, Møller HJ, Grønbaek H.
    Scand J Immunol; 2014 Dec 19; 80(6):417-23. PubMed ID: 25346048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.